Furthermore the efficacy of the JAK2 inhibitor Ruxolitinib is currently being investigated in combination with cisplatin in clinical trials in non-small cell lung carcinoma (NSCLC) [33]. This evidence concerns the gene JAK2 and non-small cell lung carcinoma.